BLSM 10-K & 10-Q changes, risk factors and insider trading

BlossomHill Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations · CIK 1839970 · All filings on SEC.gov

Everything below is quoted or computed from BlossomHill Therapeutics, Inc.'s public SEC filings. It is not a recommendation to buy or sell. Automated comparisons can contain errors; confirm with the original filing.

At a glance

6Form 4 filings reporting open-market purchases (last 180 days)

0Form 4 filings reporting open-market sales (last 180 days)

Jump to: Annual report (10-K) · Quarterly report (10-Q) · Insider transactions · 13F holders

What changed in the latest 10-K

Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare..

What changed in the latest 10-Q

Comparison not available: Not available: fewer than two 10-Q filings on EDGAR to compare (only one so far)..

BLSM insider buying and selling (Form 4)

Since 2026-04-11, insiders reported open-market purchases in 6 Form 4 filings (6 insiders, 2 trade dates, 1,573,900 shares, about $25.2M) and open-market sales in 0 filings. Net open-market shares: 1,573,900 (purchases minus sales); net value about $25.2M.Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.

Trade date	Insider	Transaction	Shares	Price	Value	Owned after	Filing
2026-08-10	Gordon Carl L Director	Conversion	1,049,283	—	—	2,089,279	SEC
2026-08-10	Gordon Carl L Director	Conversion	1,039,996	—	—	1,039,996	SEC
2026-08-10	Gordon Carl L Director	Open-market purchase	625,000	$16.00	$10.0M	2,714,279	SEC
2026-08-10	Orbimed Capital Gp Viii Llc Director	Conversion	1,039,996	—	—	1,039,996	SEC
2026-08-10	Orbimed Capital Gp Viii Llc Director	Conversion	1,049,283	—	—	2,089,279	SEC
2026-08-10	Orbimed Capital Gp Viii Llc Director	Open-market purchase	625,000	$16.00	$10.0M	2,714,279	SEC
2026-08-10	Schmid John P. Director	Open-market purchase	6,000	$16.00	$96.0K	6,000	SEC
2026-08-10	Cormorant Private Healthcare Fund Vi, Lp 10% owner	Open-market purchase	312,500	$16.00	$5.0M	3,614,034	SEC
2026-08-10	Cormorant Private Healthcare Fund Vi, Lp 10% owner	Conversion	1,599,993	—	—	1,599,993	SEC
2026-08-10	Cormorant Private Healthcare Fund Vi, Lp 10% owner	Conversion	1,701,541	—	—	3,301,534	SEC
2026-08-10	Agrawal Sundeep Director	Conversion	578,524	—	—	578,524	SEC
2026-08-10	Keyes Jason A Chief Financial Officer	Open-market purchase	700	$16.00	$11.2K	700	SEC
2026-08-10	Liptak Vincent Paul General Counsel	Open-market purchase	2,200	$16.00	$35.2K	111,412	SEC
2026-08-10	Liptak Vincent Paul General Counsel	Conversion	22,687	—	—	22,687	SEC
2026-08-10	Li Yishan Director, Executive Chairman, 10% owner	Conversion	113,435	—	—	1,714,117	SEC
2026-08-10	Li Yishan Director, Executive Chairman, 10% owner	Conversion	124,779	—	—	124,779	SEC
2026-08-10	Li Yishan Director, Executive Chairman, 10% owner	Conversion	1,600,682	—	—	1,600,682	SEC
2026-08-10	Cui Jingrong Jean Director, President and CEO, 10% owner	Conversion	1,600,682	—	—	1,600,682	SEC
2026-08-10	Cui Jingrong Jean Director, President and CEO, 10% owner	Conversion	124,779	—	—	124,779	SEC
2026-08-10	Cui Jingrong Jean Director, President and CEO, 10% owner	Conversion	113,435	—	—	1,714,117	SEC
2026-08-07	Liptak Vincent Paul General Counsel	Open-market purchase	2,500	$15.80	$39.5K	109,212	SEC

Well-known investors holding BLSM (13F)

None of the 59 investors we track reported a position in their latest 13F.

Coming soon: email alerts when BLSM files, watchlists and downloadable comparisons.